Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.
- Three APAS Independence instruments sold and invoiced in Q1 FY27
- Installed base increased to 37 instruments across eight global pharmaceutical customers
- First-half FY27 sales and evaluations expected to reach eight units
- PSC Biotech appointed sole sales agent across the US, Canada and Singapore
- $1.4 million cash balance, with $3.9 million of expected or committed inflows
Three pharmaceutical sales open FY27
Clever Culture Systems Ltd (ASX:CC5) has put three APAS Independence instruments into the revenue column in the first quarter of FY27, including two sales to Novo Nordisk in Europe and one to AstraZeneca in the United States. The Adelaide medical technology company says the result marks a positive start to its planned “land and expand” strategy with large pharmaceutical customers.
The installed base rose to 37 instruments from 34 at the end of FY26, while the number of global pharmaceutical customers held at eight. CCS expects first-half sales and customer evaluations to reach eight units, matching the company’s full-year FY26 sales figure, although that target includes instruments still under evaluation rather than completed sales alone.
The Novo Nordisk order carries significance beyond the two instruments themselves. CCS is developing an integration with Novo Nordisk’s global laboratory information management system, and says the principal connectivity work has been completed, substantially reducing the technical development risk. Further enhancements are expected to be substantially completed in early calendar 2027, which could support consideration of APAS deployments across additional sites, though no wider rollout has been announced.
Pipeline conversion becomes the next test
CCS says three of its existing pharmaceutical customers are expected to complete evaluations in the first half of FY27, with the company reporting that APAS performance has met expectations in those cases. It also expects to finalise a paid evaluation with a new Top-20 pharmaceutical company in the second quarter. The company’s earlier Novo Nordisk follow-up order already included the LIMS integration work now being advanced.
Two existing global pharmaceutical customers are in final procurement discussions, while a new single-site pharmaceutical manufacturer is also nearing a purchase commitment. CCS says purchase orders from the two existing customers are expected in the December quarter, and installation of the single-site system is being planned before the end of calendar 2026. These remain expected milestones rather than completed contracts.
PSC Biotech broadens the sales route
CCS has appointed PSC Biotech as its sole sales agent for pharmaceutical manufacturing markets in the United States, Canada and Singapore. PSC Biotech will identify and qualify opportunities, while CCS retains responsibility for closing sales and keeps the ongoing software and service fees. The arrangement extends the company’s reach beyond its direct focus on major global drugmakers, following the PSC Biotech sales channel appointment announced earlier in October.
PSC Biotech has committed to purchase an APAS Independence instrument for use at the Biotechnique facility in York, Pennsylvania. CCS says the site will be qualified for routine use and serve as a US centre of excellence. The filing does not quantify expected revenue from the agency arrangement, so its commercial value will depend on qualified opportunities converting into completed sales.
Cash position rests on receipts and loan extension
CCS ended September with $1.405 million in cash and recorded a $317,000 net operating cash outflow for the quarter. Customer receipts totalled $1.486 million, supplemented by $770,000 from the FY26 research and development tax incentive, while total net cash outflow was $292,000 after investing and financing movements.
The company expects at least $3.9 million of cash inflows over the next two quarters, including $1.9 million in receivables at quarter end, of which $700,000 had arrived in October, and $2 million of committed or advanced customer inflows. Against that, $1.6 million of unsecured loan facilities, including interest of $80,000, is due for repayment on 31 December. CCS expects to seek an extension of up to 12 months on broadly similar terms, but the filing records that as a plan rather than a completed refinancing.
Bottom Line?
The commercial story is improving, but the near-term investment case still turns on converting evaluations and expected receipts while securing the December loan extension.
Questions in the middle?
- How many of the four advanced sales opportunities will become firm contracts and cash receipts in the December quarter?
- Will the Novo Nordisk integration lead to additional site deployments after completion of the remaining enhancements?
- Can CCS extend the $1.6 million unsecured facilities before maturity without changing the cost or terms of its working-capital funding?